<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Clinical syndromes of pulmonary toxicity caused by antineoplastic agents</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Clinical syndromes of pulmonary toxicity caused by antineoplastic agents</h1>
<div class="graphic"><div class="figure"><div class="ttl">Clinical syndromes of pulmonary toxicity caused by antineoplastic agents</div><div class="cntnt"><table cellspacing="0"><colgroup span="3" width="33%"></colgroup> <tbody> <tr> <td class="subtitle1">Syndromes</td> <td class="subtitle1">Description</td> <td class="subtitle1">Examples of implicated agents</td> </tr> <tr> <td>Acute bronchoconstriction</td> <td>Evidence of airflow limitation (eg, wheezing, prolonged expiratory phase, reduced FEV<sub>1</sub>)</td> <td>Carboplatin, cyclophosphamide, etoposide, paclitaxel, rituximab, vinorelbine</td> </tr> <tr> <td>Infusion reaction</td> <td> <p>Acute onset of symptoms/signs (eg, angioedema, flushing, itching, urticaria, arthralgias, bronchoconstriction, dyspnea, hypotension, hypoxemia, nausea, or back pain) during or shortly after infusion</p> May be caused by mast cell/basophil activation or cytokine release in a systemic inflammatory reaction</td> <td>Platinum drugs, taxanes, rituximab, l-asparaginase, carfilzomib, cytarabine, etoposide</td> </tr> <tr> <td>Alveolar hemorrhage</td> <td>Dyspnea, sometimes hemoptysis, diffuse radiographic opacities, hypoxemia, BAL fluid with evidence of hemorrhage</td> <td>All-trans retinoic acid, bevacizumab, crizotinib, docetaxel, erlotinib, etoposide, fludarabine, gefitinib, gemcitabine, irinotecan, lenalidomide, sorafenib, sunitinib</td> </tr> <tr> <td>Eosinophilic pneumonia</td> <td>Dyspnea, diffuse radiographic pulmonary opacities, hypoxemia, and BAL fluid eosinophilia (&gt;20% eosinophils), sometimes with peripheral eosinophilia</td> <td>Bleomycin, lenalidomide, fludarabine, gemcitabine</td> </tr> <tr> <td>Hypersensitivity pneumonitis</td> <td> <p>Dyspnea and radiographic pulmonary opacities developing within hours to days of treatment due to a cell-mediated (Type IV) delayed hypersensitivity reaction</p> May be associated with pulmonary eosinophilia</td> <td>Bleomycin, methotrexate, cytarabine, dactinomycin</td> </tr> <tr> <td>Interstitial pneumonitis</td> <td>Dyspnea, cough, sometimes fever, diffuse or focal radiographic opacities (eg, septal thickening, ground glass opacities, consolidation) and nonspecific BAL findings</td> <td>Bleomycin, mitomycin, methotrexate, cyclophosphamide, gemcitabine, tyrosine-kinase inhibitors (eg, dasatinib, imatinib), taxanes</td> </tr> <tr> <td>Radiation recall</td> <td> <p>Appearance of radiographic opacities in areas of prior irradiation in response to treatment with a cytotoxic agent</p> Often associated with cough and dyspnea</td> <td>Carmustine, doxorubicin, etoposide, gefitinib, gemcitabine, paclitaxel and trastuzumab</td> </tr> <tr> <td>Non-cardiogenic pulmonary edema</td> <td>Pulmonary edema without evidence of heart failure or increase in left atrial pressure</td> <td>Mitomycin, cytarabine, gemcitabine, interleukin-2</td> </tr> <tr> <td>Capillary leak syndrome</td> <td>Noncardiogenic pulmonary edema associated with diffuse peripheral edema and sometimes intravascular hypovolemia</td> <td>Docetaxel, interleukin-2</td> </tr> <tr> <td>Acute lung injury, ARDS</td> <td>Noncardiogenic pulmonary edema PLUS evidence of acute inflammation (eg, fever, elevated neutrophils in BAL fluid)</td> <td>Dactinomycin, bleomycin, cytarabine, gemcitabine, mitomycin</td> </tr> <tr> <td>Pulmonary veno-occlusive disease</td> <td>A form of pulmonary hypertension with mixed pre-capillary, capillary, and post-capillary occlusion. CT findings include diffuse or mosaic ground glass opacities, septal lines, pulmonary artery enlargement, and mediastinal adenopathy</td> <td>Bleomycin, carmustine, cisplatin, cyclophosphamide, gemcitabine, mitomycin</td> </tr> </tbody></table></div><div class="graphic_footnotes">FEV<sub>1</sub>: forced expiratory volume in one second; BAL: bronchoalveolar lavage; ARDS: acute respiratory distress syndrome; CT: computed tomography.</div><div id="graphicVersion">Graphic 117782 Version 1.0</div></div></div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
